Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab vs Rituximab in Childhood SDNS and FRNS
NCT05786768Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obinutuzumab in nephrotic syndrome, sponsored by Assistance publique - Hôpitaux de Paris. Started Oct 2023; status: recruiting.
02
Drugs
obinutuzumab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT05786768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05786768.